Abstract
Since their introduction in the 1980s, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have emerged as the one of the best-selling medication classes to date, with numerous trials demonstrating powerful efficacy in preventing cardiovascular outcomes. As our understanding of low-density lipoprotein cholesterol (LDL-C) and atherosclerosis continues to grow, the concept of 'lower is better' has corresponded with a more is better' approach to statin-based therapy. This review provides a detailed understanding of the clinical efficacy and safety of statins with a particular emphasis on the third generation drug, rosuvastatin.
MeSH terms
-
Atherosclerosis / drug therapy
-
Atherosclerosis / etiology
-
Cardiovascular Diseases / blood
-
Cardiovascular Diseases / etiology
-
Cardiovascular Diseases / prevention & control*
-
Chemical and Drug Induced Liver Injury
-
Cholesterol, LDL / blood
-
Fluorobenzenes / adverse effects
-
Fluorobenzenes / therapeutic use*
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
-
Hypercholesterolemia / blood
-
Hypercholesterolemia / complications
-
Hypercholesterolemia / drug therapy*
-
Kidney Diseases / chemically induced
-
Muscular Diseases / chemically induced
-
Pyrimidines / adverse effects
-
Pyrimidines / therapeutic use*
-
Risk Assessment
-
Risk Factors
-
Rosuvastatin Calcium
-
Sulfonamides / adverse effects
-
Sulfonamides / therapeutic use*
-
Treatment Outcome
Substances
-
Cholesterol, LDL
-
Fluorobenzenes
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Pyrimidines
-
Sulfonamides
-
Rosuvastatin Calcium